Objectives: We performed a meta-analysis of transcatheter mitral valve implantation Background: It remains unclear whether VIV/VIR-TMVI reduces mortality as
| INTRODUCTION
Bioprosthetic-valve structural deterioration with severe regurgitation or stenosis and explantation because of deterioration occurs respectively in approximately three-fourth and three-fifth of patients undergoing mitral valve (MV) replacement (MVR) at 20 years, and the expected bioprosthetic-valve durability is approximately 17 years. 1 In patients undergoing MV repair, the 15-year incidence of recurrent (moderate or severe) mitral regurgitation (MR) is less than 15%. 2 Especially in patients suffering from severe comorbidities, a high risk of morbidity and mortality attends typically on redo MV surgery (MVS), which prompts cardiologists to need less invasive alternative therapies. 3 Indeed, in patients undergoing redo MVS, advanced age, very high European System for Cardiac Operative Risk Evaluation (Euro-
SCORE) II or Society of Thoracic Surgeons Predicted Risk of Mortality
(STS-PROM), preoperative severe left ventricular (LV) systolic dysfunction, severe pulmonary hypertension, renal failure on dialysis, and previous coronary artery bypass grafting are independently associated with hospital mortality. 4 Transcatheter mitral valve implantation (TMVI) by the off-label use of transcatheter aortic valve implantation (TAVI) devices has developed and refined on safe and effective management of the variety of pathologies after MVS. 3 To the best of our knowledge, however, no randomized controlled trial (RCT) and only two small-size comparative study 5, 6 
of TMVI for deteriorated bioprosthetic valves (valve-in-valve [VIV]-TMVI) and/or failed annuloplasty rings (valve-in-ring [VIR]-TMVI) versus redo MVS have been
conducted to date. Thus, it remains unclear whether VIV/VIR-TMVI reduces mortality as compared with redo MVS. In the present article,
we performed a meta-analysis of VIV/VIR-TMVI, comparing observed early (30-day) mortality with predicted operative mortality.
| METHODS
All studies including ≥10 patients undergoing VIV/VIR-TMVI were identified using a 2-level search strategy. First, databases including MEDLINE and EMBASE were searched current through 24 July 2018 using Web-based search engines (PubMed and OVID). Second, relevant studies were identified through a manual search of secondary sources including references of initially identified articles and a search of reviews and commentaries. All references were downloaded for consolidation, elimination of duplicates, and further analysis. Search terms included valve-in-valve or valve-in-ring; and mitral.
Studies considered for inclusion met the following criteria: the study population was patients with a deteriorated mitral bioprosthetic valve or a failed mitral annuloplasty ring; patients underwent VIV/VIR-TMVI; the study included ≥10 patients undergoing either VIV-TMVI or VIR-TMVI; and main outcomes included at least early (30-day) allcause mortality. Data regarding detailed inclusion criteria, TMVI device type, duration of follow-up, predicted operative mortality (such as STS-PROM and EuroSCORE), and 30-day/late (including 30-day) all-cause mortality were abstracted (as available) from each individual study.
Although serial or multicenter publications reporting accumulating numbers of patients were identified, the publications with the largest number of datasets were retained.
For each study, data regarding observed 30-day mortality and predicted operative mortality (STS-PROM) were used to generate risk ratios (RRs) and 95% confidence intervals (CIs). Study-specific estimates were combined using the inverse variance-weighted average of logarithmic RRs in the random-effects model. One-group meta-analyses of 30-day/late mortality rates were also performed in the random-effects model. Between-study heterogeneity was analyzed by means of standard chi-square tests.
Sensitivity analyses were performed to assess the contribution of each study to the pooled RR estimate (for observed 30-day mortality versus predicted operative mortality) by excluding individual studies one at a time and recalculating the pooled estimates for the remaining studies (one-study-removed meta-analysis). 
| RESULTS
Of 270 potentially relevant articles screened initially, 17 eligible studies 5-21 including a total of 1017 patients undergoing VIV/VIR-TMVI were identified (Table 1) . Only two small-size study 5, 6 compared VIV-TMVI with redo MVS, and one of them using a propensity-score analysis. 6 Eleven studies 5, 6, [8] [9] [10] 13, 15, [17] [18] [19] 21 Table S1 , and implanted transcatheter heart valves and approaches in Supplementary Table S2 . The TA approach was exclusively applied in seven studies, [8] [9] [10] 13, 15, 19, 21 the TS approach was exclusively used in two studies 6, 12 and the VIR patients of one study, 20 and both the approaches were utilized in seven | 901 studies. 5, 7, 11, 14, 16, 17, 18 In total, the TA and TS approach was used in The predicted operative and observed 30-day/late mortality in each study were summarized in Table 2 . In all but four studies, To assess publication bias, we generated a funnel plot of the logarithm of effect size (RR for observed 30-day mortality versus predicted operative mortality) versus the reciprocal of standard error for each study. The linear-regression test detected marginally significant funnel-plot asymmetry (P = 0.07), which raised the possibility of publication bias. Thus, we undertook a sensitivity analysis using the trim-and-fill method, 22 There were no significant differences in the inhospital mortality and 2-year event-free survival rates between the VIV-TMVI and redo MVR groups. 6 In the study, 6 VIR, and VIMAC groups, the 30-day and 1-year event (death and cardiovascular surgery)-free survival rates were significantly lower in the VIR/VIMAC-combined group than in the VIV group. 12 The challenges of VIR-TMVI could be attributed to the following factors: 1)
predicting the ring deformability is difficult when TMVI makes initiallyelliptical rings circular and 2) the existence of native anterior leaflet and insufficient fixation within rings limit the optimal implantation of transcatheter valves. 7 Frerker et al 14 focused on outcomes of VIV/VIR-TMVI stratified by the access route. The 30-day mortality rate was 15.4% in 13 TA-TMVI patients and 9.1% in 11 TS-TMVI patients, and survival up to 4 years showed a benefit in TS patients which may argue the TS approach as a primary strategy of TMVI. Whereas, Yoon et al 7 showed no significant differences in procedural-related and in 1-year mortality rates between the TS and TA access groups. Despite less invasiveness of the TS approach, technically more challenging coaxial alignment of the transcatheter valve with the deteriorated bioprosthesis or failed ring must be achieved.
14 Our analysis must be viewed in the context of its limitations.
First, we compared observed 30-day mortality in patients undergoing VIV/VIR-TMVI with predicted operative mortality in these patients (virtual control) because only two comparative study 5, 6 were published. Actual 30-day mortality after redo MVS, however, may be higher than predicted operative mortality. Second, the present results may be influenced by publication bias favoring TMVI.
Although exhaustively searching the available literature minimized the risk, the statistical test suggested funnel plot asymmetry. After adjustment using the trim-and-fill method, 22 however, observed 30-day mortality was still significantly lower than predicted operative mortality. Third, patients enrolled in the study by Yoon et al 7 from
TMVR registry (25 centers in Europe and North America) and the study by Grover et al 16 from the TVT registry (United States) may include duplicate patients enrolled in other studies. The duplication, however, were unable to be revealed because of unavailable individual patient data. Finally, including TA-VIV-TMVI, TS-VIV-TMVI, TA-VIR-TMVI, and TS-VIR-TMVI patients must lead to a certain amount of heterogeneity. We performed a sensitivity analysis exclusively combining TA-VIV-TMVI studies, however, which included only 111 patients.
| CONCLUSIONS
The results of the present meta-analysis demonstrated that VIV/VIR-TMVI brought about relatively low early and midterm (6-month to 5-year) mortality and that observed 30-day mortality was significantly lower than predicted operative mortality.
